The much-anticipated Dr. Agarwal’s Health Care IPO is set to open on January 29, 2025, and will close on January 31, 2025. This Book Built IPO aims to raise around ₹3,027.26 crores, comprising a fresh issue of ₹300.00 crores and an offer for sale (OFS) of up to ₹2,727.26 crores. The face value of the equity shares is ₹1 each.
Dr. Agarwal’s Health Care IPO Price Band and Quota
- Price Band: ₹382 to ₹402 per share
- Retail Investor Quota: 35%
- Qualified Institutional Buyers (QIB): 50%
- High Net Worth Individuals (HNI): 15%
The IPO shares will be listed on BSE and NSE with an expected listing date of February 5, 2025. The IPO allotment date is scheduled for February 3, 2025.
Financial Performance
Dr. Agarwal’s Health Care has showcased consistent growth:
- Revenue: ₹1,376.45 crores in 2024 vs. ₹1,031.49 crores in 2023
- Net Profit: ₹95.05 crores in 2024 vs. ₹103.23 crores in 2023
Despite a slight dip in profits, the revenue growth highlights the company’s robust performance and scalability in the healthcare sector.
Dr. Agarwal’s Health Care IPO Date & Price Band Details
| Category | Details |
|---|---|
| IPO Open Date: | January 29, 2025 |
| IPO Close Date: | January 31, 2025 |
| Face Value: | ₹1 Per Equity Share |
| IPO Price Band: | ₹382 to ₹402 Per Share |
| Issue Size: | Approx ₹3,027.26 Crores |
| Fresh Issue: | Approx ₹300 Crores |
| Offer for Sale: | Approx 6,78,42,284 Equity Shares |
| Issue Type: | Book Built Issue |
| IPO Listing: | BSE & NSE |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
About Dr. Agarwal’s Health Care Overview
Services:
- Surgical: Cataract surgery, refractive surgery (LASIK, SMILE), glaucoma surgery, retinal detachment surgery, corneal transplants, oculoplastic procedures.
- Non-Surgical: Comprehensive eye examinations, medical eye care (glaucoma, diabetic retinopathy, macular degeneration), pediatric ophthalmology, non-surgical vision correction.
- Optical Products & Services: Sale of eyeglasses, contact lenses, and other optical products; personalized eyeglass fittings and contact lens consultations.
Network:
- Extensive Reach: Operates a vast network of clinics and hospitals across India, ensuring widespread accessibility.
- International Presence: Expanding its footprint with clinics in several African countries.
Key Strengths:
- Strong Brand Reputation: Recognized for its expertise, quality of care, and patient-centric approach.
- Experienced Team: Employs a team of highly skilled ophthalmologists, optometrists, and other eye care professionals.
- Advanced Technology: Utilizes state-of-the-art technology and equipment for diagnosis and treatment.
- Focus on Innovation: Continuously invests in research and development to offer the latest advancements in eye care.
Dr. Agarwal’s Health Care: Risks and Strengths
Strengths:
- Market Leader: Holds a significant market share in the Indian eye care market, giving it a competitive advantage.
- Strong Brand Equity: Established a strong brand reputation built on trust, quality, and patient satisfaction.
- Large Network: Extensive reach across India and expanding international presence ensures access to a large patient base.
- Experienced Team: Boasts a team of highly skilled and experienced ophthalmologists and other medical professionals.
- Technological Advancements: Utilizes advanced technology and equipment for diagnosis and treatment, enhancing patient care.
Risks:
- Competition: Faces competition from other established players in the healthcare sector, including hospitals and individual practitioners.
- Regulatory Compliance: Operating in a highly regulated industry, compliance with safety, health, and other regulations is crucial.
- Doctor Dependency: Relies heavily on the expertise and availability of skilled doctors, which can be challenging to maintain.
- Reputational Risk: Maintaining a strong brand reputation is crucial, and any negative publicity or medical malpractice incidents can significantly impact the business.
- Technological Disruption: Rapid advancements in technology and the emergence of new treatment options require continuous adaptation and investment.
Dr. Agarwal’s Health Care IPO Market Lot
The Dr. Agarwal’s Health Care IPO has a minimum market lot of 35 shares, requiring an application amount of ₹14,070. Retail investors can apply for a maximum of 13 lots, which equals 490 shares at a total investment of ₹1,96,980.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 35 | ₹14,070 |
| Retail Maximum | 13 | 490 | ₹1,96,980 |
| S-HNI Minimum | 14 | 525 | ₹2,11,050 |
| B-HNI Minimum | 68 | 2,520 | ₹10,13,040 |
Dr. Agarwal’s Health Care IPO Allotment & Listing Dates
The much-awaited Dr. Agarwal’s Health Care IPO is set to open on January 29, 2025, and will close on January 31, 2025. Investors eagerly anticipating this IPO should mark their calendars, as the IPO allotment date is scheduled for February 3, 2025, and the IPO listing date is expected on February 5, 2025.
| Type | Date |
|---|---|
| IPO Open Date: | January 29, 2025 |
| IPO Close Date: | January 31, 2025 |
| Basis of Allotment: | February 3, 2025 |
| Refunds: | February 4, 2025 |
| Credit to Demat Account: | February 4, 2025 |
| IPO Listing Date: | February 5, 2025 |
Promoters of Dr. Agarwal’s Health Care IPO
The promoters of the company include a team of renowned medical professionals and family trusts associated with the Agarwal family. Key promoters are Dr. Amar Agarwal, Dr. Athiya Agarwal, Dr. Adil Agarwal, Dr. Anosh Agarwal, Dr. Ashvin Agarwal, and Dr. Ashar Agarwal. Additionally, the Dr. Amar Agarwal Family Trust, Dr. Adil Agarwal Family Trust, Dr. Anosh Agarwal Family Trust, Dr. Ashvin Agarwal Family Trust, and Dr. Ashar Agarwal Family Trust are also part of the promoter group. Other entities include Dr. Agarwal’s Eye Institute and Dr. Agarwal’s Eye Institute Private Limited, further highlighting their extensive contributions to the organization.
Dr. Agarwal’s Health Care IPO Company Financial Report
In 2024, the company reported a revenue of ₹1,376.45 crores, reflecting significant growth compared to ₹1,031.49 crores in 2023. However, the profit declined to ₹95.05 crores in 2024, down from ₹103.23 crores in 2023. This showcases a year-on-year increase in revenue but a dip in profitability.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
|---|---|---|---|---|
| 2022 | ₹713.78 | ₹657.02 | ₹43.16 | ₹1,026.13 |
| 2023 | ₹1,031.49 | ₹947.90 | ₹103.23 | ₹1,825.17 |
| 2024 | ₹1,376.45 | ₹1,235.88 | ₹95.05 | ₹2,752.82 |
| September 2024 | ₹837.94 | ₹777.59 | ₹39.56 | ₹3,393.41 |
Dr. Agarwal’s Health Care IPO Valuation – FY2024
| KPI | Values |
|---|---|
| ROE: | 3.14% |
| ROCE: | 5.95% |
| EBITDA Margin: | 26.91% |
| PAT Margin: | 4.70% |
| Debt to equity ratio: | 0.70 |
| Earning Per Share (EPS): | ₹3.14 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 6.21% |
| Net Asset Value (NAV): | ₹50.53 |
Dr. Agarwal’s Health Care Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | 62.50 | 107.11 | 12.97% | 481.93 | 19,059.20 Cr. |
| Max Healthcare Institute Limited | 10.89 | 95.88 | 12.58% | 86.54 | 6,849.00 Cr. |
| Fortis Healthcare Limited | 7.93 | 82.11 | 7.82% | 101.48 | 6,892.92 Cr. |
| Global Health Limited | 17.80 | 57.49 | 16.46% | 108.17 | 3,275.11 Cr. |
| Narayana Hrudayalaya Limited | 38.86 | 33.14 | 27.37% | 141.98 | 5,018.25 Cr. |
| Krishna Institute of Medical Sciences Limited | 7.75 | 79.79 | 16.96% | 228.47 | 2,498.14 Cr. |
| Aster DM Healthcare Limited | 3.60 | 136.07 | 3.63% | 71.62 | 3,698.90 Cr. |
| Rainbow Children’s Medicare Limited | 21.38 | 67.90 | 17.24% | 124.03 | 1,296.90 Cr. |
Objects of the Issue
- Repayment or Prepayment of Borrowings (Full or Partial)
- Funding General Corporate Purposes, and Unidentified Inorganic Acquisitions.
Dr. Agarwal’s Health Care IPO Review
- Canara Bank
- DRChoksey FinServ
- Emkay Global
- Hem Securities
- IDBI Capital
- Marwadi Shares
- Nirmal Bang
- SBICAP Securities
- Sharekhan
- SMC Global
- Sushil Finance
- Swastika Investmart
- Ventura Securities
- Geojit
- Reliance Securities
- Capital Market
- BP Wealth
- ICICIdirect
- Choice Broking
Dr. Agarwal’s Health Care IPO Registrar
KFin Technologies Limited
Phone: 04067162222, 04079611000
Email: ahcl.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/
Dr. Agarwal’s Health Care IPO Lead Managers aka Merchant Bankers
- Kotak Mahindra Capital Company Limited
- Morgan Stanley India Company Pvt Ltd
- Jefferies India Private Limited
- Motilal Oswal Investment Advisors Limited
Company Address
Dr. Agarwal’s Health Care Limited
1 st Floor, Buhari Towers
No.4, Moores Road, Off Greams Road,
Near Asan Memorial School, Chennai 600 006
Phone: +91 44 4378 7777
Email: secretarial@dragarwal.com
Website: https://dragarwals.co.in/
FAQs about Dr. Agarwal’s Health Care IPO
The IPO opens on January 29, 2025, and closes on January 31, 2025.
The price band is set at ₹382 to ₹402 per equity share.
The face value of each share is ₹1.
The minimum lot size is 35 shares, and retail investors can apply for up to 13 lots.
The IPO aims to raise around ₹3,027.26 crores, including a fresh issue of ₹300 crores and an OFS of ₹2,727.26 crores.
The shares will be listed on BSE and NSE.
The allotment date is February 3, 2025.
The shares will be credited to the investors’ Demat accounts on February 4, 2025.
The company’s strong brand reputation, large network, and technological advancements make it a leader in the eye care industry.
The lead managers include:
Kotak Mahindra Capital Company Limited
Morgan Stanley India Company Pvt Ltd
Jefferies India Private Limited
Motilal Oswal Investment Advisors Limited
The IPO proceeds will be used for:
Repayment/prepayment of certain borrowings
Funding general corporate purposes
Unidentified inorganic acquisitions
The promoters include Dr. Amar Agarwal, Dr. Athiya Agarwal, Dr. Adil Agarwal, and family trusts such as Dr. Amar Agarwal Family Trust and Dr. Adil Agarwal Family Trust.
The company reported a revenue of ₹1,376.45 crores in FY 2024, with a net profit of ₹95.05 crores.
The risks include high competition, regulatory challenges, and dependency on skilled doctors.
Disclaimer: This information is for general knowledge and informational purposes only and does not constitute financial, investment, or other professional advice.
Note: This information is based on the IPO schedule and details available as of January 9, 2025. Please refer to the official IPO documents for the most up-to-date information.
